Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. As an antibody with reduced fucose content, obinutuzumab induces greater ADCC activity than rituximab in vitro using human cancer cell lines. Obinutuzumab also demonstrated an increased ability to induce direct cell death when compared to rituximab.
Pemetrexed Injection is a folate analog metabolic inhibitor. Pemetrexed Injection is indicated in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
ZEPZELCA is an alkylating drug. ZEPZELCA is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
TIBSOVO (ivosidenib) is an inhibitor of isocitrate dehydrogenase 1 (IDH1) enzyme. TIBSOVO is indicated in combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1(IDH1) mutation as detected by an FDA-approved test in adults 75 years or older
Clolar (clofarabine) injection contains clofarabine, a purine nucleoside metabolic inhibitor. Clolar is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.
HALAVEN contains eribulin mesylate, a microtubule dynamics inhibitor. HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.
Vitamin K is a fat-soluble vitamin that comes in two forms — K1 (phylloquinone) and K2 (menaquinone). Vitamin K1, the most common form, is mainly found in plant foods, especially dark leafy greens. K2, on the other hand, is only found in animal foods and fermented plant foods, such as natto.